A major weapon against cancer
- The cancer immunotherapy market for checkpoint inhibitors will increase to nearly $9 billion across the world’s major pharmaceutical markets in 2022.
- The successes of immunotherapies dominate the literature and drive current research on cancer.
- Immune approaches to cancer therapy have been validated by the approval of drugs such as Keytruda®, Opdivo®, Yervoy® and Provenge®.
- Immune modulators such as anti-PD-1 (Keytruda®)/anti-PD-L1 (Tecentriq®) mAb’s boost T-cell activity in response to tumors and are widely used in high priority therapeutic development programs by Big Pharma.
- Side effects are significant but manageable.
- Analysts estimate that cancer immunotherapies could account for $35 billion annually within 10 years
The Susavion advantage
- Susavion’s multivalent peptide technology engages strategic targets on multiple cell types that stimulate proliferation and maturation of active lymphocytic and monocytic immune cells, thereby expanding the innate immune system.
- Susavion’s lead drug promotes maturation of dendritic cells and presentation of antigens to T cells to initiate a humoral immune response.
- Susavion developed several peptides that turn on activating receptors and other peptides that turn off inhibitory receptors (checkpoint blockade) on key immune cells.
- Susavion’s peptides are excellent complements and extend the efficacy of other immunotherapies.
- Susavion’s platform drugs are produced synthetically, relatively inexpensive to produce at high purity, stable, and easily distributed world-wide.
- Susavion’s drugs have broad application against cancers, low toxicity, and thus are potentially game changers.